Angptl3, angiopoietin-like 3; apo, apolipoprotein; apoEKO, homozygous for apoE gene knockout allele; hypl, a recessive mutation in Angptl3 gene causing hypolipidemia; apoEKO-hypl, homozygous for both apoE gene knockout and hypl allele; HL, hepatic lipase; FPLC, fast protein liquid chromatography we investigated the effects of hypl mutation against hyperlipidemia and atherosclerosis in apolipoprotein E knockout (apoEKO) mice. ApoEKO mice with hypl mutation (apoEKO-hypl) exhibited a significant reduction of VLDL-TG, VLDL-cholesterol and plasma apoB levels compared with apoEKO mice. Hepatic VLDL-TG secretion was comparable between both apoE-deficient mice. Turnover studies revealed that the clearance of both 3 H-TG-labeled and 125 I-labeled VLDL was significantly enhanced in apoEKO-hypl mice. Postprandial plasma TG levels also decreased in apoEKO-hypl mice. Both LPL and hepatic lipase activities in the post-heparin plasma increased significantly in apoEKO-hypl mice, explaining the enhanced lipid metabolism.
Introduction
The accrued evidence that lipid-lowering therapy limits the progression of atherosclerosis and reduces the events of coronary artery diseases is overwhelming (1, 2) .
The focus has been on the reduction of low-density lipoprotein (LDL)-cholesterol (3, 4) .
Recent studies have also pointed out the importance of reducing triglyceride (TG)-rich lipoproteins such as chylomicrons, very low-density lipoproteins (VLDL) and their remnants and of raising high-density lipoprotein (HDL)-cholesterol (5, 6) . In addition, postprandial hypertriglyceridemia is mentioned as an independent risk factor for atherogenesis (7, 8) .
In a colony of KK mice with mild obesity, hyperlipidemia and diabetes, we found mutant mice (KK/Snk, previously KK/San) that were characterized by a significant decrease in plasma lipid levels mainly due to the reduction of TG-rich lipoproteins, despite their obesity and diabetes. Genetic studies for the mutation, named hypolipidemia (hypl), in KK/Snk mice identified a 4-bp nucleotide insertion in exon 6 of a gene encoding angiopoietin-like 3 (Angptl3), which causes a premature stop codon after a frameshift (9) . Angptl3 is a secretory protein of 70 kD expressed predominantly in the liver, and has a signal sequence, coiled-coil domain and fibrinogen-like domain similar to those of other angiopoietin families (10, 11) . In KK/Snk mice with the homozygous hypl mutation, Angptl3 expression was markedly decreased, probably due to the instability of mutant mRNA, resulting in a hypolipidemic trait (9) . In contrast, adenovirus-mediated overexpression of Angptl3 or intravenous injection of the purified protein elicited a marked elevation in circulating plasma lipid levels (9) . We also investigated the regulatory mechanism of Angptl3 on the metabolism of TG-rich lipoproteins (12) . VLDL turnover studies revealed that KK/Snk mice exhibited enhanced VLDL-TG clearance compared with wild-type KK mice. Moreover, addition of recombinant human ANGPTL3 protein directly inhibited lipoprotein lipase (LPL) and hepatic lipase (HL) activities in in vitro studies (12) . Taken together, we consider that Angptl3 is a new class of metabolic modulators affecting lipid homeostasis.
Over the past several years, significant advances have been made in our understanding of new, alternative mechanisms by which LPL and HL modulate lipoprotein metabolism and the development of atherosclerosis (13, 14) . Studies using transgenic and knockout animal models have shown that plasma LPL and HL are involved in the susceptibility to atherosclerosis in addition to regulating plasma lipid levels (15) (16) (17) (18) . In our previous in vitro study, it was also predicted that the hypl mutation, which markedly reduces Angptl3 expression, would increase the plasma LPL and HL activities (12) . Thus, in the present study, to elucidate the role of Angptl3 in atherogenesis, we investigated the effects of the hypl mutation on hyperlipidemia and atherosclerosis, which are developed due to the accumulation of TG-rich lipoproteins in the circulation in apolipoprotein (apo) E-deficient mice (19). The hypl mutation enhanced lipolysis of TG-rich lipoproteins and their clearance in the liver, and resulted in a marked reduction of plasma lipid and apoB levels, in apoE-deficient mice. Both LPL and HL activities in the post-heparin plasma were increased significantly by the hypl mutation, explaining such an enhanced lipid metabolism. Atherogenic lesions in the aortic valves observed in the absence of apoE were also significantly decreased in mice carrying the hypl mutation. These findings revealed that a reduction in Angptl3 expression has protective effects against hyperlipidemia and atherosclerosis even in the absence of apoE. Therefore, it was considered that Angptl3 plays an important role in by guest, on September 21, 2017 www.jlr.org Downloaded from atherogenesis and that Angptl3 might be a useful target in the development of new treatments for atherosclerosis.
Materials and methods

Mice
Hypolipidemic KK/Snk mice from Nagoya University were bred in our eluted at a constant flow rate of 50 l/min with PBS (pH 7.4, containing 1 mM EDTA).
Fractions of 25 l were collected and assayed for total cholesterol and TG levels as described above.
Immunoblot analysis
Plasma samples (1 l per lane) were separated on 2-15% gradient gels (Daiichi Pure Chemicals) and the proteins were transferred onto nitrocellulose membranes (Bio-Rad). The membranes were incubated with goat anti-mouse apoB antibody (Santa Cruz Biotechnology). Horseradish peroxidase-labeled anti-goat immunoglobulin G (Chemicon) was used as a secondary antibody, and apoB bands were detected by ECL Western blotting detection reagents (Amersham Biosciences). The intensity of the bands was estimated by an imaging analyzer.
Postprandial TG response
Mice were fasted for 16 h. After taking a basal blood sample by tail bleeding at t = 0, animals received an intragastric load of 400 l of olive oil. Additional blood samples were drawn at 1, 2, 3, 4, 5 and 6 h after the oral administration of olive oil.
Plasma TG levels were measured at the time points as described above.
In vivo hepatic VLDL-TG production
Mice were fasted for 16 h, and injected intravenously via the tail vein with Triton WR1339 (400 mg/kg body weight) using 20% (w/v) Triton solution in 0.9%
NaCl. Blood samples were drawn from the tail vein at 0, 30, 60 and 120 min after the Triton injection and analyzed for TG as described above. 
Assay of LPL and HL enzyme activities
Post-heparin plasma was prepared from blood taken 10 min after intravenous injection of heparin at a dose of 100U/kg body weight into male mice fasted for 5 h. 
Pathological analysis
The cross-sectional lesion area was evaluated according to a modified method 
Statistics
Student's t-test was used to compare mean values between the wild-type and hypl mice and between the apoEKO and apoEKO-hypl mice.
Results
Plasma lipid levels and lipoprotein profiles
Expression levels of Angptl3 mRNA in the liver of the hypl and apoEKO-hypl mice were markedly lower than those in the wild-type and apoEKO mice, respectively ( Figure 1A and B) . Plasma lipid levels in fasted hypl mice in the presence and absence of apoE are summarized in Table 1 . The levels of all lipids in the hypl and apoEKO-hypl mice were significantly lower than those in the wild-type and apoEKO mice, respectively. In particular, in the apoEKO-hypl mice, the TG levels were markedly reduced, and the levels of TG and NEFA were comparable to those in the wild-type mice. The reduction in the plasma TG levels was primarily due to the scarcity of VLDL-sized particles with and without apoE (Figure 2A and B) . Plasma cholesterol was mainly found in HDL-sized particles with apoE, and the peak of HDL-cholesterol in the hypl mice was reduced to 68.7% compared to that in the wild-type mice (Figure the apoEKO mice ( Figure 2B ). We also investigated the difference of apoB100/apoB48 composition in the lipoproteins of the apoEKO and apoEKO-hypl mice. Contents of apoB100 and apoB48 in the apoEKO-hypl mice were decreased by 53.6% and 36.7%, respectively, compared with those in the apoEKO mice (Figure 3) . These results indicate that the hypl mutation of the Angptl3 gene resulted in a reduction of apoB-containing lipoproteins in the absence of apoE.
In vivo VLDL metabolism
To determine whether the hypl mutation affects the production of TG by the liver, we injected Triton WR1339 into mice and monitored the secretion of endogenous VLDL-TG over time. As shown in Fig. 4B , the VLDL-TG secretion rate was comparable between the apoEKO and apoEKO-hypl mice, although a 25% decrease was observed in the hypl mice compared with the wild-type mice ( Figure 4A ). However, there were no changes in weight nor pathology of the liver between the wild-type and hypl mice and between the apoEKO and apoEKO-hypl mice (data not shown).
Therefore, these results indicate that the hypl mutation has little effect on hepatic VLDL-TG production, particularly in the absence of apoE.
Next, to investigate whether the plasma TG decrease in the apoEKO-hypl mice is due to enhanced TG clearance, the apoEKO and apoEKO-hypl mice were injected with 3 H-TG-labeled VLDL. As shown in Figure 5A , the 3 H-labeled TG were more rapidly cleared from the circulation in the apoEKO-hypl mice. To determine the metabolic pathway of the lipoproteins containing apoB, we also performed a turnover study using 125 I-labeled VLDL as a marker for whole particle clearance. As a result, the injected 125 I-labeled VLDL apoB disappeared significantly faster from the plasma in the apoEKO-hypl mice compared with the apoEKO mice ( Figure 5B ). These data indicate that the reduction of plasma lipid levels by hypl mutation in the absence of apoE is due to an enhancement of TG hydrolysis and whole particle clearance of VLDL and their remnants.
Postprandial TG response
To investigate the postprandial response of plasma TG levels, mice received an intragastric load of olive oil. Plasma TG levels after an intragastric fat load in the apoEKO-hypl mice were significantly lower than those in the apoEKO mice ( Figure   6B ), and showed a gradual increase similar to that seen in wild-type mice ( Figure 6A ).
In contrast, no such postprandial response was observed in the hypl mice ( Figure 6A ).
These results indicate that postprandial hypertriglyceridemia was prevented from developing by the hypl mutation even in the absence of apoE.
LPL and HL activities of post-heparin plasma
To elucidate whether the enhanced lipid metabolism by the hypl mutation results from the increase of lipase activity, we determined LPL and HL activities of post-heparin plasma in the apoEKO and apoEKO-hypl mice. As shown in Figure 7A and B, both activities of LPL and HL increased significantly in the apoEKO-hypl mice compared with the apoEKO mice. These results suggest that the reduction of Angptl3 increases lipase activity in vivo, resulting in the enhancement of lipolysis and clearance of TG-rich lipoproteins in the hypl mutant mice.
Atherosclerotic lesions in aortic valves
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To examine the effect of the hypl mutation on atherogenesis in apoE-deficient mice, a histological study was conducted. As shown in Figure 8A , the apoEKO mice exhibited typical fatty streak lesions with foam cells and cholesterol crystals in the aortic sinus, whereas the apoEKO-hypl mice had only small fatty streak lesions. The cross-sectional lesion area of the apoEKO-hypl mice was significantly smaller than that of the apoEKO mice by 69% (3.608 ± 1.921 x 10 5 m 2 vs. 11.559 ± 6.204 x 10 5 m 2 , P < 0.01) ( Figure 8B) . These results indicate that the hypl mutation has protective effects against atherosclerosis even when associated with apoE deficiency.
Discussion
In the present study, we clarified that the hypl mutation, which reduces Angptl3 expression, enhanced lipolysis and the clearance of TG-rich lipoproteins, and prevented hypertriglyceridemia, hypercholesterolemia and atherosclerosis, often observed in apoE-deficient mice, from developing.
We reported previously that adenovirus-mediated overexpression of Angptl3 gene or intravenous injection of human ANGPTL3 protein increased the plasma TG levels in mice (9, 12) . These findings suggest that the plasma TG level varies accoding to the plasma Angptl3 level. The Angptl3 mRNA expression levels in hypertriglyceridemic apoEKO mice was 38% lower than that in wild-type mice, but was not statistically significant ( Figure 1A and B) . The decreased Angptl3 mRNA expression may be a reactive response, although the mechanism is not yet clear, because the TG levels in the apoEKO mice were 4 times higher due to the accumulation of TG-rich lipoproteins, compared with those in the wild-type mice.
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Plasma lipid levels are thought to be regulated by a balancing of their secretion and clearance. The rate of TG secretion from the liver was not affected by the hypl mutation in apoE-deficient mice as shown by the high plasma TG levels ( Figure   4B ), but was 25% lower in hypl mice with apoE compared with wild-type mice, exhibiting relatively low plasma TG levels ( Figure 4A ). Our previous study also
showed that the secretion rate in hypl-mutated KK/Snk mice was 15% lower or the same, compared with wild-type KK mice (12,27), whose mean plasma TG level (273.9 ± 38.5 mg/dl) was between that of the apoEKO and wild-type mice used in this study (9) . These data indicate that the hypl mutation, which induces a decrease in Angptl3 expression, appears to reduce basal hepatic TG secretion although the effect is not recognized in mice showing markedly high levels of plasma TG basally.
We analyzed the effect of Angptl3 on the metabolism of VLDL accumulated in the circulating blood in the absence of apoE. A metabolic experiment of VLDL containing 3 H-labeled TG revealed that VLDL-TG was decreased significantly and more rapidly in the apoEKO-hypl mice, compared with the apoEKO mice ( Figure 5A ).
We clarified that the activity of LPL increased in apoEKO-hypl mice as shown in Figure 7A . In contrast, in the previous report, we showed that human ANGPTL3
protein inhibited LPL activity dose-dependently in vitro (12). Yagyu et al. (15) also
showed that an overexpression of LPL combined with apoE deficiency caused a decrease in plasma TG levels. Thus, these results suggest that the reduction in plasma TG levels in the apoEKO-hypl mice, as shown in Table 1 and Figure 2B , is due to the increased TG hydrolytic activity of LPL, which was enhanced by the decrease in increases in the hypl-mutated mice in this study (Figure 7B) , and previously reported that HL activity is slightly inhibited by Angptl3 (12) . Therefore, the HL-mediated cholesteryl ester clearance may also contribute to the reduction of plasma cholesterol levels in the apoEKO-hypl mice.
The hypl mutation resulted in significantly inhibiting the increase of plasma TG levels in a fat-loading test of olive oil in both the presence and absence of apoE ( Figure 6A and B) . This suggests that the metabolism of chylomicrons and their remnants, as well as VLDL, might be promoted by increased LPL activity due to the reduction of plasma Angptl3. Shimada et al. (38) also reported that an overexpression of LPL led to an enhanced catabolism and clearance of chylomicrons in their metabolic study using LPL transgenic mice. Therefore, the effective clearance of chylomicrons may be one of the reasons why the hypl mutation leads to the reduction of plasma lipids and apoB levels in this study.
We also found a significant decrease of NEFA in hypl-mutated mice in both the presence and absence of apoE ( Table 1) . In transgenic mice overexpressing LPL specifically in both the skeletal and cardiac muscles, Levak-Frank et al. (39) have demonstrated that LPL augments the uptake of NEFA in the muscles. Therefore, the increased LPL activity owing to a reduction in Angptl3 expression may enhance uptake of NEFA in the peripheral tissues.
As shown in Figure 8 , the hypl mutation was found to have protective effects against atherosclerosis caused by apoE deficiency. It has been reported that the atherosclerosis formed by the apoE deficiency is suppressed due to a modification in some of the genes involved in lipid metabolism, causing, for example, an overexpression of LPL, a deficiency in the LPL inhibitor, apoCIII, a deficiency of the These results also indicate that the irregular lipoprotein profile owing to apoE deficiency is improved by a reduction in TG-rich lipoproteins. The hypl mutation also enhanced the catabolism and clearance of VLDL in the absence of apoE ( Figure 5A and B), through the increase of lipase activity (Figure 7A and B) . Therefore, it is likely that the suppression of atherosclerosis in the apoEKO-hypl mice observed in this study is mainly due to this improvement of the lipoprotein profile. In addition, an overexpression of LPL leads to increased HDL-cholesterol levels, which is anti-atherogenic. However, HDL-cholesterol was not increased in the hypl mice ( Figure   2A ). Thus, it does not appear that a decreased Angptl3 expression suppresses atherogenesis by means of increasing the levels of HDL. Further investigation is needed to elucidate whether Angptl3 has direct atherogenic effects on the arterial wall. 
